RenovoRx (NASDAQ:RNXT) PT Raised to $8.25

RenovoRx (NASDAQ:RNXT) had its target price increased by Ascendiant Capital Markets from $8.00 to $8.25 in a report issued on Thursday morning, Benzinga reports. They currently have a buy rating on the stock.

RenovoRx Price Performance

Shares of RNXT opened at $1.13 on Thursday. RenovoRx has a 52-week low of $0.53 and a 52-week high of $2.35. The business’s 50 day moving average price is $1.13 and its two-hundred day moving average price is $1.24.

RenovoRx (NASDAQ:RNXT) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.10) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On RenovoRx

A hedge fund recently bought a new stake in RenovoRx stock. Nixon Peabody Trust Co. acquired a new stake in shares of RenovoRx, Inc. (NASDAQ:RNXT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 97,165 shares of the company’s stock, valued at approximately $223,000. Nixon Peabody Trust Co. owned approximately 0.91% of RenovoRx as of its most recent SEC filing. Institutional investors and hedge funds own 3.10% of the company’s stock.

About RenovoRx

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.